Abstract
One factor that impacts on microglial activation is the interaction between the ubiquitously expressed CD200 and CD200R, which is expressed only on microglia in the brain. Decreased signalling through CD200R, when CD200 expression is reduced, results in microglial activation and may, at least in part, explain the increased cell activity that is observed with age, in models of Alzheimer’s and Parkinson’s disease as well as in the human diseases. There is evidence of increased microglial activation in CD200-deficient mice, and isolated microglia prepared from these mice are more reactive to inflammatory stimuli like Toll-like receptor 2 and 4 agonists, and interferon-γ. Here, we examined the impact of CD200 deficiency on amyloid-β (Aβ)-induced changes in microglia and report, perhaps unexpectedly, that the effect of Aβ was attenuated in microglia prepared from CD200-deficient mice. The evidence indicates that this is a consequence of increased phagocytosis, associated with increased lysosomal activity in CD200-deficient microglia. The data suggest that mTOR-related signalling is decreased in these cells and that inhibiting mTOR by rapamycin increases phagocytosis. Thus, while the findings to date have emphasized the anti-inflammatory effects of CD200-CD200R interaction, the present evidence indicates a previously unreported impact on lysosomal function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KH, Lynch MA (2007) CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci 27:8309–8313. doi:10.1523/JNEUROSCI.1781-07.2007
Lyons A et al (2009) Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Behav Immun 23:1020–1027. doi:10.1016/j.bbi.2009.05.060
Cox FF, Carney D, Miller AM, Lynch MA (2012) CD200 fusion protein decreases microglial activation in the hippocampus of aged rats. Brain Behav Immun 26:789–796. doi:10.1016/j.bbi.2011.10.004
Miller AM, Deighan BF, Henrich-Noack P, Nolan Y, Lynch MA (2011) Analysis of the impact of CD200 on neurodegenerative diseases, neurodegenerative diseases—processes, prevention, protection and monitoring. In: Chang RC-C (ed), ISBN: 978–953–307-485-6, InTech
Koning N, Swaab DF, Hoek RM, Huitinga I (2009) Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol 68:159–167. doi:10.1097/NEN.0b013e3181964113
Tan MS et al (2013) NLRP3 polymorphisms are associated with late-onset Alzheimer’s disease in Han Chinese. J Neuroimmunol 265:91–95. doi:10.1016/j.jneuroim.2013.10.002
Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF (2009) Decreased expression of CD200 and CD200 receptor in Alzheimer’s disease: a potential mechanism leading to chronic inflammation. Exp Neurol 215:5–19. doi:10.1016/j.expneurol.2008.09.003
Walker, D.G., L.F. Lue (2013) Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains? Future Neurol 8. doi:10.2217/fnl.13.14
Zhang S et al (2011) CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson’s disease. J Neuroinflammation 8:154. doi:10.1186/1742-2094-8-154
Denieffe S, Kelly RJ, McDonald C, Lyons A, Lynch MA (2013) Classical activation of microglia in CD200-deficient mice is a consequence of blood brain barrier permeability and infiltration of peripheral cells. Brain Behavior and Immunity 34:86–97. doi:10.1016/J.Bbi.2013.07.174
Costello DA, Lyons A, Denieffe S, Browne TC, Cox FF, Lynch MA (2011) Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice: a role for Toll-like receptor activation. J Biol Chem 286:34722–34732. doi:10.1074/jbc.M111.280826
Noonan J, Tanveer R, Klompas A, Gowran A, McKiernan J, Campbell VA (2010) Endocannabinoids prevent beta-amyloid-mediated lysosomal destabilization in cultured neurons. J Biol Chem 285:38543–38554. doi:10.1074/jbc.M110.162040
Halle A et al (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857–865. doi:10.1038/ni.1636
Costello DA, Carney DG, Lynch MA (2015) Alpha-TLR2 antibody attenuates the Abeta-mediated inflammatory response in microglia through enhanced expression of SIGIRR. Brain Behav Immun 46:70–79. doi:10.1016/j.bbi.2015.01.005
Jana M, Palencia CA, Pahan K (2008) Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer’s disease. J Immunol 181:7254–7262
Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009) CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 29:11982–11992. doi:10.1523/JNEUROSCI.3158-09.2009
Man SM, Kanneganti TD (2015) Regulation of inflammasome activation. Immunol Rev 265:6–21. doi:10.1111/imr.12296
Fu R, Shen Q, Xu P, Luo JJ, Tang Y (2014) Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol 49:1422–1434. doi:10.1007/s12035-013-8620-6
Sokolowski JD, Mandell JW (2011) Phagocytic clearance in neurodegeneration. Am J Pathol 178:1416–1428. doi:10.1016/j.ajpath.2010.12.051
Liu S et al (2012) TLR2 is a primary receptor for Alzheimer’s amyloid beta peptide to trigger neuroinflammatory activation. J Immunol 188:1098–1107. doi:10.4049/jimmunol.1101121
Song M et al (2011) TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer’s disease. J Neuroinflammation 8:92. doi:10.1186/1742-2094-8-92
Hayakawa K et al (2016) CD200 restrains macrophage attack on oligodendrocyte precursors via toll-like receptor 4 downregulation. J Cereb Blood Flow Metab 36:781–793. doi:10.1177/0271678X15606148
Varnum MM, Kiyota T, Ingraham KL, Ikezu S, Ikezu T (2015) The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer’s disease. Neurobiol Aging 36:2995–3007. doi:10.1016/j.neurobiolaging.2015.07.027
Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S (2007) LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J 26:313–324. doi:10.1038/sj.emboj.7601511
Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9:324–337. doi:10.1038/nri2546
Lyons A, Downer EJ, Costello DA, Murphy N, Lynch MA (2012) Dok2 mediates the CD200Fc attenuation of Abeta-induced changes in glia. J Neuroinflammation 9:107. doi:10.1186/1742-2094-9-107
Acknowledgments
The authors gratefully acknowledge funding from the Science Foundation Ireland to MAL (07/IN.1/B949 and 11/PI/1014). AL was supported by a post-doctoral fellowship from the Health Research Board Ireland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Animal experimentation was performed under a licence granted by the Minister for Health and Children (Ireland) under the Cruelty to Animals Act 1876 and the European Community Directive, 86/609/EEC, and in accordance with local ethical guidelines.
Rights and permissions
About this article
Cite this article
Lyons, A., Minogue, A.M., Jones, R.S. et al. Analysis of the Impact of CD200 on Phagocytosis. Mol Neurobiol 54, 5730–5739 (2017). https://doi.org/10.1007/s12035-016-0223-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-016-0223-6